Charles Schwab’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $64.4M | Buy |
790,112
+58,470
| +8% | +$4.22M | 0.01% | 1062 |
|
|
2026
Q1 | $49.8M | Sell |
731,642
-3,291
| -0.4% | -$233K | 0.01% | 1154 |
|
|
2025
Q4 | $55.8M | Buy |
734,933
+32,175
| +5% | +$2.34M | 0.01% | 1072 |
|
|
2025
Q3 | $43.1M | Sell |
702,758
-4,946
| -0.7% | -$258K | 0.01% | 1253 |
|
|
2025
Q2 | $34.6M | Buy |
707,704
+45,630
| +7% | +$2.17M | 0.01% | 1334 |
|
|
2025
Q1 | $33.7M | Sell |
662,074
-23,635
| -3% | -$1.18M | 0.01% | 1331 |
|
|
2024
Q4 | $31M | Sell |
685,709
-21,021
| -3% | -$900K | 0.01% | 1439 |
|
|
2024
Q3 | $26.2M | Buy |
706,730
+47,902
| +7% | +$1.6M | 0.01% | 1542 |
|
|
2024
Q2 | $20.1M | Buy |
658,828
+39,535
| +6% | +$1.28M | ﹤0.01% | 1678 |
|
|
2024
Q1 | $18M | Buy |
619,293
+8,375
| +1% | +$235K | ﹤0.01% | 1675 |
|
|
2023
Q4 | $16.8M | Buy |
610,918
+14,155
| +2% | +$324K | ﹤0.01% | 1692 |
|
|
2023
Q3 | $13.4M | Buy |
596,763
+23,288
| +4% | +$866K | ﹤0.01% | 1756 |
|
|
2023
Q2 | $23.3M | Buy |
573,475
+15,166
| +3% | +$742K | 0.01% | 1389 |
|
|
2023
Q1 | $27M | Sell |
558,309
-1,676
| -0.3% | -$76.6K | 0.01% | 1240 |
|
|
2022
Q4 | $21.4M | Buy |
559,985
+12,497
| +2% | +$520K | 0.01% | 1379 |
|
|
2022
Q3 | $27.5M | Buy |
547,488
+18,950
| +4% | +$928K | 0.01% | 1157 |
|
|
2022
Q2 | $21.2M | Buy |
528,538
+16,158
| +3% | +$567K | 0.01% | 1367 |
|
|
2022
Q1 | $19.1M | Buy |
512,380
+13,201
| +3% | +$509K | 0.01% | 1586 |
|
|
2021
Q4 | $19.9M | Buy |
499,179
+10,569
| +2% | +$405K | 0.01% | 1585 |
|
|
2021
Q3 | $18.2M | Sell |
488,610
-4,298
| -0.9% | -$177K | 0.01% | 1663 |
|
|
2021
Q2 | $20.8M | Buy |
492,908
+19,943
| +4% | +$855K | 0.01% | 1554 |
|
|
2021
Q1 | $22.4M | Buy |
472,965
+21,964
| +5% | +$1.3M | 0.01% | 1436 |
|
|
2020
Q4 | $27.5M | Buy |
451,001
+7,924
| +2% | +$467K | 0.01% | 1174 |
|
|
2020
Q3 | $20.7M | Buy |
443,077
+13,032
| +3% | +$642K | 0.01% | 1179 |
|
|
2020
Q2 | $21.8M | Buy |
430,045
+46,893
| +12% | +$2.3M | 0.01% | 1103 |
|
|
2020
Q1 | $17.1M | Buy |
383,152
+8,038
| +2% | +$405K | 0.01% | 1117 |
|
|
2019
Q4 | $18M | Buy |
375,114
+22,566
| +6% | +$959K | 0.01% | 1285 |
|
|
2019
Q3 | $11.9M | Buy |
352,548
+28,411
| +9% | +$1.24M | 0.01% | 1496 |
|
|
2019
Q2 | $14.6M | Sell |
324,137
-33,294
| -9% | -$1.31M | 0.01% | 1363 |
|
|
2019
Q1 | $13.5M | Buy |
357,431
+38,487
| +12% | +$1.29M | 0.01% | 1393 |
|
|
2018
Q4 | $10.9M | Buy |
318,944
+36,090
| +13% | +$1.3M | 0.01% | 1396 |
|
|
2018
Q3 | $13.3M | Sell |
282,854
-12,781
| -4% | -$529K | 0.01% | 1446 |
|
|
2018
Q2 | $9.97M | Buy |
295,635
+72,308
| +32% | +$2.25M | 0.01% | 1607 |
|
|
2018
Q1 | $6.04M | Buy |
223,327
+34,839
| +18% | +$883K | ﹤0.01% | 1840 |
|
|
2017
Q4 | $3.14M | Buy |
188,488
+9,693
| +5% | +$164K | ﹤0.01% | 2141 |
|
|
2017
Q3 | $3.58M | Buy |
178,795
+24,366
| +16% | +$477K | ﹤0.01% | 2057 |
|
|
2017
Q2 | $2.83M | Buy |
154,429
+28,668
| +23% | +$386K | ﹤0.01% | 2100 |
|
|
2017
Q1 | $1.24M | Buy |
125,761
+6,840
| +6% | +$82.8K | ﹤0.01% | 2359 |
|
|
2016
Q4 | $1.3M | Buy |
118,921
+6,160
| +5% | +$64.6K | ﹤0.01% | 2346 |
|
|
2016
Q3 | $1.58M | Buy |
112,761
+53,740
| +91% | +$437K | ﹤0.01% | 2249 |
|
|
2016
Q2 | $415K | Sell |
59,021
-41,765
| -41% | -$306K | ﹤0.01% | 2657 |
|
|
2016
Q1 | $650K | Sell |
100,786
-3,763
| -4% | -$65.3K | ﹤0.01% | 2479 |
|
|
2015
Q4 | $3.39M | Buy |
104,549
+6,828
| +7% | +$201K | ﹤0.01% | 1768 |
|
|
2015
Q3 | $2.61M | Buy |
97,721
+13,469
| +16% | +$576K | ﹤0.01% | 1909 |
|
|
2015
Q2 | $4.06M | Buy |
84,252
+15,824
| +23% | +$923K | 0.01% | 1689 |
|
|
2015
Q1 | $4.16M | Buy |
68,428
+2,930
| +4% | +$179K | 0.01% | 1634 |
|
|
2014
Q4 | $3.39M | Buy |
65,498
+7,145
| +12% | +$315K | 0.01% | 1706 |
|
|
2014
Q3 | $2.57M | Buy |
58,353
+8,093
| +16% | +$253K | ﹤0.01% | 1821 |
|
|
2014
Q2 | $1.31M | Buy |
50,260
+15,474
| +44% | +$331K | ﹤0.01% | 2204 |
|
|
2014
Q1 | $910K | Buy |
34,786
+14,195
| +69% | +$381K | ﹤0.01% | 2337 |
|
|
2013
Q4 | $350K | Buy |
20,591
+648
| +3% | +$11.4K | ﹤0.01% | 2724 |
|
|
2013
Q3 | $447K | Buy |
+19,943
| New | +$347K | ﹤0.01% | 2594 |
|
Other funds holding PTCT
RI
JT
Charles Schwab's PTCT Position: Q2 2026 in Review
Charles Schwab increased its PTC Therapeutics (PTCT) stake by 8% in Q2 2026, buying an estimated $4.22M and bringing the position to 790,112 shares worth $64.4M. The position accounts for 0.01% of the portfolio, ranked #1062.
Charles Schwab first reported a position in PTCT in Q3 2013 and has held it in 52 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- Charles Schwab held 790,112 shares of PTC Therapeutics worth $64.4M as of Q2 2026.
- Charles Schwab bought 58,470 PTC Therapeutics shares in Q2 2026, an estimated $4.22M.
- PTC Therapeutics made up 0.01% of Charles Schwab's portfolio in Q2 2026, its #1062 holding.
- Charles Schwab first reported a position in PTC Therapeutics in Q3 2013 and has held it in 52 quarters since.
- 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.